Revance Therapeutics (RVNC) Receives a Buy from Mizuho Securities

By Carrie Williams

Mizuho Securities analyst Difei Yang maintained a Buy rating on Revance Therapeutics (RVNCResearch Report) today and set a price target of $34.00. The company’s shares closed last Monday at $12.70, close to its 52-week low of $9.88.

According to TipRanks.com, Yang has currently no stars on a ranking scale of 0-5 stars, with an average return of -3.9% and a 32.8% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals Inc, Alder Biopharmaceuticals, and Audentes Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Revance Therapeutics with a $32.50 average price target.

See today’s analyst top recommended stocks >>

Based on Revance Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $37.39 million. In comparison, last year the company had a GAAP net loss of $32.83 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Revance Therapeutics, Inc. is a clinical stage biotechnology company. It is engaged in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic, and therapeutic applications.